Opioids represent widely prescribed and abused medications, although their signal transduction mechanisms are not well understood. Here we present the 1.8 Å high-resolution crystal structure of the human d-opioid receptor (d-OR), revealing the presence and fundamental role of a sodium ion in mediating allosteric control of receptor functional selectivity and constitutive activity. The distinctive d-OR sodium ion site architecture is centrally located in a polar interaction network in the seven-transmembrane bundle core, with the sodium ion stabilizing a reduced agonist affinity state, and thereby modulating signal transduction. Site-directed mutagenesis and functional studies reveal that changing the allosteric sodium site residue Asn 131 to an alanine or a valine augments constitutive b-arrestin-mediated signalling. Asp95Ala, Asn310Ala and Asn314Ala mutations transform classical d-opioid antagonists such as naltrindole into potent b-arrestin-biased agonists. The data establish the molecular basis for allosteric sodium ion control in opioid signalling, revealing that sodium-coordinating residues act as 'efficacy switches' at a prototypic G-protein-coupled receptor.
1
. These opioid GPCRs are activated by endogenous peptides (endorphins, enkephalins, dynorphins, nociceptin/orphanin FQ), natural alkaloids (opiates), and an expanding number of small molecule agonists through interactions with the orthosteric site located in the extracellular portion of the seven-transmembrane (7TM) bundle. Despite the progress made in understanding GPCR activation 2 , the underlying molecular mechanisms and structural features responsible for many processes including signal transduction, allosteric modulation, functional selectivity and constitutive activity remain elusive 3, 4 .
Insights from 1.8 Å resolution d-OR structure
Pioneering studies initiated in 1973 on opioid receptors revealed that physiological concentrations of sodium alter opiate ligand binding and signalling, albeit by unknown mechanisms 5, 6 . To address the molecular basis for the striking allosteric effect of sodium on opioid receptor function, we crystallized the human d-OR (residues 36-338) with an amino-terminal b 562 RIL (BRIL) fusion protein (BRIL-dOR(DN/DC)) and determined the crystal structure in complex with the subtype-selective ligand naltrindole 7 at 1.8 Å resolution (Fig. 1 , Extended Data Table 1 and Methods). Importantly, the high-resolution BRIL-dOR(DN/DC)-naltrindole structure contains the wild-type protein sequence, including an intact intracellular loop 3 (ICL3), providing the opportunity to study an opioid receptor that closely resembles a near native conformational state. The 1.8 Å structure of the human d-OR is similar to the 3.4 Å Mus musculus d-OR structure fused to T4 lysozyme 8 at the ICL3 site (root mean squared deviation of 0.91 Å over all structurally characterized Ca atoms) with the distinction that the atomic details of regions crucial for receptor activity are revealed. These include: (1) a fully resolved ICL3 adopting a 'closed' inactive state conformation (Fig. 2) ; (2) a detailed molecular characterization of the orthosteric site with watermediated ligand-receptor interactions (Extended Data Fig. 1) ; (3) a distinct conformation of the human third extracellular loop (ECL3) (Extended Data Fig. 2) ; and, importantly, (4) a high-resolution characterization of the allosteric sodium site, water molecules and a comprehensive network of hydrogen-bond interactions inside the 7TM core ( Fig. 1 and Extended Data Figs 3, 4) .
All ICL3 residues are well resolved in the BRIL-dOR(DN/DC)-naltrindole structure. The side-chain guanidinium group of Arg 257 6.31 (superscripts indicate residue numbering using the Ballesteros-Weinstein nomenclature 9 ) appears to have a key role in stabilizing ICL3 by forming an extensive hydrogen-bonding network with the main-chain carbonyls of Leu 240 5.67 , Arg 244 ICL3 and Val 243
ICL3
, and a salt bridge with the carboxylate group of Asp 253 6.27 (Fig. 2a) . The Leu 246  ICL3 and  Val 243 ICL3 side chains insert back in the helical bundle and form a hydrophobic cluster with Val 150 3.54 , Leu 240 5.67 and Leu 256 6.30 (Fig. 2b ). The loop also interacts with helix III via a water-mediated hydrogenbond network between the main-chain carbonyl groups of Leu 246 ICL3 and Val 150 3.54 , and the side chain of Arg 239 5.66 (Fig. 2d ). These atomic details suggest a stable 'closed' conformation of ICL3 in the inactive d-OR, which tethers the intracellular ends of helices V and VI. Although it contrasts with the more 'exposed' ICL3 conformations in the thermostabilized A 2A adenosine receptor (A 2A AR; Protein Data Bank (PDB) accession 3PWH) 10 and rhodopsin (PDB 3CAP) 11 ( Fig. 2c) , the ICL3 in d-OR is similar to that observed in the lower resolution NOP structure (PDB 4EA3) 12 ( Fig. 2b) . A high sequence conservation of ICL3 in all four opioid receptors, which signal primarily via Ga i/o -proteins, suggests that ICL3 can adopt a similar 'closed' conformation in inactive states of all opioid receptor subtypes. The closed conformation of ICL3 may have a role in stabilizing the inactive state in opioid receptors, and thus compensate for the lack of a stabilizing 'ionic lock' in these receptors, which have a hydrophobic Leu 6.30 instead of the usual Glu 6.30 side chain that is required for an ionic lock.
In the orthosteric pocket, the BRIL-dOR(DN/DC)-naltrindole structure reveals an extensive network of water-mediated interactions with the morphinan group of naltrindole, including interactions with residues in helix V and ECL2 (Extended Data Fig. 1a ). For the ECL3 region, a key selectivity determinant for peptide binding to classical opioid receptors 13 , we observe that the side chain of Arg 291 ECL3 constrains a distinct loop conformation between helices VI and VII through hydrogen-bonding networks with the main-chain carbonyl groups of Val 287 ECL3 and Trp 284 6.58 , positioning the latter for a p2p interaction with naltrindole (Extended Data Fig. 2 ). This conformation of ECL3 is quite different from the one observed for the lower resolution M. musculus d-OR structure 8 , which has an asparagine side chain instead of the Asp 290 ECL3 seen in the human d-OR. These high-resolution details of the binding pocket and ligand interactions in the human d-OR orthosteric site provide an excellent framework for designing new d-OR ligands 14 and allosteric modulators 15 with improved selectivity and functional profiles.
Unique features of the d-OR sodium site
Evidence for the presence of a sodium ion in the allosteric site is similar to that observed in the high-resolution A 2A AR structure (PDB 4EIY) 16 , including: (1) electron density showing coordination of the proposed sodium position by five oxygen atoms; (2) short distances observed between the ion and coordinating oxygens (,2.4 Å ); and (3) calculations of ion valence (Supplementary Table 1 ). The cavity harbouring the allosteric sodium is formed by the side chains of 16 residues, 15 of which are highly conserved in class A GPCRs ( Fig. 1 Fig. 3b ), the majority (,70%) of class A GPCRs have a hydrophobic residue in this position, and in the high-resolution A 2A AR structure the side chain of Leu 87 3.35 is pointing towards the lipidic membrane 16 . By contrast, in the BRILdOR(DN/DC)-naltrindole structure the Asn 131 3.35 side chain points into the sodium pocket, placing its oxygen (OD1) and nitrogen (ND2) atoms between the ion and the orthosteric pocket (Fig. 1) . These exact atom positions are occupied by two water molecules in the allosteric sodium site of the A 2A AR structure (Extended Data Fig. 3a) . In addition to the key role of the Asn 131 3.35 side-chain OD1 atom in sodium coordination, the ND2 atom is hydrogen bonded to both side-chain OD1 and main-chain carbonyl atoms of Asp 128 3.32 via a water molecule (Fig. 1) ; the latter residue occupies a central position deep in the orthosteric site and establishes a salt bridge with the nitrogen group of naltrindole. These interactions between the sodium ion, Asn 131 3.35 and Asp 128 3.32 establish an apparent axis of connectivity between orthosteric and allosteric regions on the receptor characterized in the inactive state. Altogether, the allosteric sodium of d-OR is coordinated by five oxygen atoms, from Asp 95 2.50 , Ser 135 3.39 and Asn 131 3.35 side chains and two structurally conserved water molecules, which comprises the first coordination shell for the sodium ion ( Fig. 1 and Extended Data Figs 3, 4) .
The second coordination shell of the sodium ion in the allosteric site is formed by the side chains of three residues (Trp 274 6.48 , Asn 310 7.45 and Asn 314 7.49 ) and two additional water molecules in contact with waters in the first shell ( Fig. 1 and Extended Data Figs 3, 4) . These conserved residues of the sodium pocket belong to two of the most wellknown class A functional motifs: CW 6.48 xP in helix VI and N 7.49 PxxY in helix VII (x denotes any residue) (Fig. 1a) , which have a critical role in GPCR activation processes 17 . As a whole, the cluster comprising the sodium ion and eight water molecules mediates extensive intrahelical hydrogen-bond networks between helices I, II, III, VI and VII in the core of the receptor, when it is stabilized in an inactive state conformation. By contrast, the activated agonist-bound structure of A 2A AR reveals a sodium site that is collapsed by an inward movement of helix VII 18 , suggesting that rearrangements in this conserved sodium pocket have a key role in the activation of class A GPCRs 2 .
Functional characterization of d-OR
To correlate the structural data obtained using BRIL-dOR(DN/DC) with the wild-type d-OR, we performed radioligand binding assays with opioid agonists and antagonists with wild-type d-OR and BRILdOR(DN/DC) constructs expressed in HEK293 and Sf9 (Spodoptera frugiperda) cells, respectively. We found that the BRIL-dOR(DN/DC) and wild-type d-OR displayed similar ligand-binding affinities (Extended  Data Table 2 ) and, when both were expressed in HEK293 cells, they displayed similar functional coupling to Ga i -mediated signalling (Extended Data Fig. 5a , b). Consistent with classical studies performed on opioid receptors in situ 5, 19, 20 , physiological concentrations of NaCl (140 mM) reduced the affinity of the d-OR peptide agonist DADLE ([D-Ala2, D-Leu5] enkephalin), which is structurally related to endogenous peptide agonists, at both wild-type d-OR expressed in HEK293 cells and BRIL-dOR(DN/DC) expressed in Sf9 cells, while having minimal effects on antagonist-binding affinity (Extended Data Table 2 ). To confirm the specificity of the sodium site, we also examined the effects of other monovalent cations on the binding of 
Sodium modulates d-OR ligand binding
Although the phenomenon of allosteric modulation of GPCR ligand affinity by sodium ions has been previously described for a number of class A GPCRs (for example, opioid, adrenergic, adenosine and dopamine receptors) [21] [22] [23] [24] , the nature of this allosteric effect, as well as sodium's affinity for the allosteric site is unknown. To quantify sodium's affinity at its allosteric binding site and to clarify the nature of the apparent negative cooperativity with respect to the peptide Table 3 and Extended Data Fig. 7 ) and discovered that mutating the sodium-anchoring d-OR residue Asn 131 3.35 into alanine or valine considerably enhanced constitutive activity for the b-arrestin pathway (Fig. 3c, d and Extended Data Fig. 7) . Notably, the b-arrestin constitutive activity of Asn131 3.35 Ala or Asn131 3.35 Val mutants exceeded the activation levels of wild-type d-OR achieved with a saturating concentration of the agonist DADLE (Fig. 3c) , whereas Ga i protein basal activity remained unaffected (Extended Data Fig. 7 ). The Asn 131 3.35 mutants increased receptor b-arrestin constitutive activity as well as DADLE-binding affinity, as compared with wildtype d-OR, albeit DADLE efficacy for the b-arrestin pathway was greatly reduced (Supplementary Table 2 and Extended Data Table 3 ). Importantly, although the Asn131 3.35 Ala mutation abolished the 'sodium effect', the receptor carrying the Asn131 3.35 Val mutation retained sodium ion binding, although with lower affinity compared to wild-type receptor ( Table 1) .
The key differences in sodium ion binding affinity between the Asn 131 3.35 mutants provided us with a model system to further clarify the role of sodium on canonical Ga i -protein-mediated signalling. Notably, the Asn131 3.35 Ala mutant was inactive whereas the Asn131 3.35 Val mutant, which partially retains the 'sodium effect', maintained Ga i activity, although with reduced agonist potency compared with the wild-type d-OR (Fig. 4a and Supplementary Table 2 ). These data indicate that a complete disruption of the interactions between Asn 131 3.35 and the sodium ion can induce high levels of constitutive activity at non-canonical b-arrestin signalling, while simultaneously abolishing canonical G-protein signalling, essentially inducing an 'efficacy switch' from the Ga i protein pathway to a b-arrestin pathway. These results reveal that the non-conserved residue Asn 131 3.35 has an essential role in controlling both d-OR functional selectivity and constitutive activity, probably through its structural role in coordinating the allosteric Results were analysed using the allosteric model summarized in Table 1 . c, The basal activity of Asn131 3.35 Ala and Asn131 3.35 Val is compared to wild type (WT) over a range of DNA dosages and their activity exceeded the one achieved with a saturating concentration of DADLE (10 mM Val responded to DADLE (10 mM) with a modest degree of stimulation (*P , 0.01 (t-test) versus no drug addition (basal)). Low-level expression was used allowing the detection of activation by a saturating concentration of DADLE. Val could contribute to this small reduction by displacing Ga i protein.
Sodium-dependent opioid pharmacology
We next examined Asp 95 2.50 , another key sodium site residue, and found that mutation of this residue into either alanine or asparagine abolished the 'sodium effect' in radioligand binding assays (Fig. 3b and Table 1 ). The small molecule agonist BW373U86 has been previously described as a selective orthosteric d-OR agonist for which binding to the receptor is minimally affected by sodium ions 26 . Consequently, BW373U86 displays a low-to-moderate reduction in G-protein and b-arrestin signalling at sodium-anchored-residue mutants compared to wild type (Fig. 4a, b) . On the other hand, the peptide agonist DADLE has a diminished potency for b-arrestin recruitment at the d-OR mutant Asp95
2.50
Ala and is inactive at both the Asn310 7.45 Ala and the Asn314 7.49 Ala mutants, while showing low-to-moderate reduction in G-protein-agonist efficacy (Supplementary Table 2 ). Importantly, we discovered that classical d-OR ligands containing a cyclopentene functional group (naltrindole, naltriben and 7-benzylidenenaltrexone (BNTX)), which display no apparent agonist activity at the b-arrestin pathway with the wild-type d-OR, gained potent b-arrestin-biased agonist activity at the Asp95
Ala sodium site mutant (Fig. 4d and Supplementary Table 2) . A similar transformative effect is observed when the sodium site residues Asn 310 7.45 and Asn 314 7 .49 were mutated to alanine (Fig. 4d and Supplementary Table 2 ). The conversion of these antagonists/weak partial agonists into b-arrestin-biased agonists by mutations in the allosteric sodium site, together with the effects of Asn 131 3.35 mutants described above, uncovered what we characterize as 'efficacy switches' within d-OR. These efficacy switches are apparently distinct from those previously reported at which only G-protein signalling was enhanced 27, 28 .
The allosteric sodium-binding pocket described here in atomic detail is potentially an attractive drug discovery target. Although the binding of small molecule allosteric modulators in this highly conserved site is unlikely to have desired subtype selectivity, extension of selective orthosteric ligands into the sodium cavity may lead to bitopic compounds with new pharmacological properties, for example, inverse agonism or strong functional bias. The detailed crystal structure may also help to identify the binding site and shed light on the mode of action for the other types of positive allosteric modulator (PAM) compounds, such as those recently reported in ref. 15 .
Our results reveal a profound and essential role for allosteric sodiumanchoring residues at specifying GPCR signal transduction and pharmacology. Mutation of sodium-anchoring residues within the allosteric site selectively modulates not only agonist binding, but also markedly changes GPCR functional activity by augmenting b-arrestin constitutive activity and introducing new patterns of biased signalling. In particular, these findings highlight the unexpectedly essential role for sodiumcoordinating amino acids as efficacy switches for GPCR signalling.
METHODS SUMMARY
The BRIL-dOR(DN/DC) construct has its first 35 amino-terminal residues (DN 35) replaced with the thermostabilized apocytochrome b 562 RIL (M7W, H102I, R106L; BRIL) and 34 carboxy-terminal residues (DC 34) deleted and was expressed in S. frugiperda (Sf9) insect cells for structural and radioactive ligand-binding experiments. Sf9 membranes were solubilized in 0.75% (w/v) n-dodecyl-b-Dmaltopyranoside and 0.15% (w/v) cholesteryl hemisuccinate in the presence of 25 mM naltrindole, and purified by immobilized metal ion affinity chromatography. Receptor crystallization was performed using the lipidic cubic phase (LCP) method. The protein-LCP mixture contained 40% (w/w) protein solution, 54% (w/w) monoolein (Sigma) and 6% (w/w) cholesterol. Crystallization trials were performed using 40 nl protein-laden LCP overlaid with 0.8 ml precipitant solution (31-34% (v/v) PEG 400, 0.095-0.12 M K/Na tartrate, 5% (v/v) ethylene glycol, 100 mM MES buffer, pH 6.1-6.2, and 1 mM naltrindole) at 20 uC. Crystallographic data were collected on the 23ID-D beamline (GM/CA CAT) of the Advanced Photon Source at the Argonne National Laboratory using a 20-mm collimated minibeam. Data sets from 47 different crystals were merged for the final data set (Supplementary Table 1 ). cAMP assays were performed in HEK293T cells co-transfected with Receptors were all transfected with 15 mg DNA revealing weak partial agonist activity of naltrindole at Ga i signalling as described previously 29, 30 .
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human wild-type d-OR or various mutants along with a split-luciferase-based cAMP biosensor (GloSensor; Promega). d-OR b-arrestin-recruitment assays were performed using the Tango assay as described in Methods. 3 H-naltrindole-binding assays were performed using Sf9 membranes expressing the crystallized construct BRIL-dOR(DN/DC) or HEK293 T-cell membrane preparations transiently expressing wild-type or mutant d-OR receptors.
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Cloning, expression and purification. The wild-type human d-OR gene (OPRD1; UniProt accession P41143) was synthesized by DNA2.0 with codon optimization for expression in S. frugiperda (Sf9), and then cloned into a modified pFastBac1 vector (Invitrogen) containing an expression cassette with a haemagglutinin signal sequence followed by a Flag tag, a 10 3 His tag and a tobacco etch virus (TEV) protease recognition site at the N terminus. Thirty-four amino acids were deleted from the C terminus (residues 339-372), and 35 residues of the N terminus (residues 1-35) of d-OR were replaced with the thermostabilized apocytochrome b 562 RIL from Escherichia coli (M7W, H102I and R106L) (BRIL) 31 protein using splicing by overlap extension PCR 32 . A Pro37Ser mutation was introduced in the N terminus of d-OR to facilitate crystallization. Recombinant baculoviruses were generated using the Bac-to-Bac system (Invitrogen) and were used to infect Sf9 insect cells at a density of 2 3 10 6 cells ml 21 at a multiplicity of infection of 5 as described previously 33 . Infected cells were grown at 27 uC for 48 h before being collected, and the cell pellets were stored at 280 uC.
Insect cell membranes were disrupted as described previously 34 . In brief, cell pellets were homogenized by douncing in a hypotonic buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and EDTA-free complete protease inhibitor cocktail tablets (Roche). Washing of the membranes was performed by repeated dounce homogenization and centrifugation in the same hypotonic buffer (once more), followed by high osmotic buffer containing 1.0 M NaCl, 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and EDTA-free complete protease inhibitor cocktail tablets (three times). Purified membranes were re-suspended in 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and 30% (v/v) glycerol, flash frozen with liquid nitrogen, and stored at 280 uC.
Before receptor purification membranes were thawed and washed once again in a buffer containing 1.0 M NaCl, 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl. Washed membranes were re-suspended in buffer containing 50 mM naltrindole (Tocris), 2 mg ml 21 iodoacetamide (Sigma), 500 mM NaCl, 50 mM HEPES, pH 7.5, and incubated at 4 uC for 1 h before solubilization. The membranes were then solubilized in 50 mM HEPES, pH 7.5, 500 mM NaCl, 0.75% (w/v) n-dodecylb-D-maltopyranoside (DDM; Anatrace), 0.15% (w/v) cholesteryl hemisuccinate (CHS; Sigma) and 25 mM naltrindole for 3 h at 4 uC. The supernatant was isolated by centrifugation at 160,000g for 45 min, and incubated in 20 mM buffered imidazole (pH 7.5), 0.7 M NaCl with 1 ml of TALON IMAC resin (Clontech) overnight at 4 uC. After binding, the resin was washed with 15 column volumes of wash buffer I (50 mM HEPES, pH 7.5, 800 mM NaCl, 10% (v/v) glycerol, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 10 mM ATP, 10 mM MgCl 2 and 50 mM naltrindole), followed by 10 column volumes of wash buffer II (50 mM HEPES, pH 7.5, 500 mM NaCl, 10% (v/v) glycerol, 0.02% (w/v) DDM, 0.004% (w/v) CHS, 50 mM imidazole and 50 mM naltrindole). The protein was then eluted by 5 column volumes of elution buffer (25 mM HEPES, pH 7.5, 500 mM NaCl, 10% (v/v) glycerol, 0.02% (w/v) DDM, 0.004% (w/v) CHS, 250 mM imidazole and 100 mM naltrindole). PD miniTrap G-25 column (GE Healthcare) was used to remove imidazole. The protein was then treated overnight with His-tagged TEV protease to cleave the N-terminal His tag and Flag tag. TEV protease and the cleaved N-terminal fragment were removed by TALON IMAC resin incubation for 1 h at 4 uC. Purified receptor was concentrated to 20 mg ml 21 with a 100 kDa molecular weight cutoff Vivaspin centrifuge concentrator (GE Healthcare). Protein purity and monodispersity were tested by SDS-PAGE and analytical size-exclusion chromatography (aSEC). Typically, the protein purity exceeded 95%, and the aSEC profile showed a single peak, indicative of receptor monodispersity. Crystallization. Receptor samples in complex with naltrindole were reconstituted into lipidic cubic phase (LCP) by mixing with molten lipid using a mechanical syringe mixer 35 . The protein-LCP mixture contained 40% (w/w) protein solution, 54% (w/w) monoolein (Sigma) and 6% (w/w) cholesterol (AvantiPolar Lipids). Crystallization trials were performed in 96-well glass sandwich plates 36 (Marienfeld) by an NT8-LCP crystallization robot (Formulatrix) using 40 nl protein-laden LCP overlaid with 0.8 ml precipitant solution in each well, and sealed with a glass coverslip. Protein reconstitution in LCP and crystallization trials was carried out at room temperature (,20-23 uC) . The crystallization plates were stored and imaged in an incubator/imager (RockImager 1000, Formulatrix) at 20 uC. Diffraction quality crystals of an average size of 50 3 10 3 3 mm were obtained within ,10 days in 31-34% (v/v) PEG 400, 0.095-0.12 M K/Na tartrate, 5% (v/v) ethylene glycol, 100 mM MES buffer, pH 6.1-6.2, and 1 mM naltrindole. Crystals were collected directly from LCP using 50 mm MiTeGen micromounts and immediately flash frozen in liquid nitrogen. X-ray data collection and processing. Crystallographic data were collected on the 23ID-D beamline (GM/CA CAT) of the Advanced Photon Source at the Argonne National Laboratory using a 20-mm collimated minibeam at a wavelength of 1.0330 Å and a MarMosaic 300 detector. To reduce radiation damage crystals were translated to a fresh position, if possible, or replaced after collecting 10 frames at 1-s exposure and 1.0u oscillation with an unattenuated beam. Data sets from 47 different crystals were integrated, scaled and merged together using HKL2000 37 (Extended Data Table 1 ). Structure determination and refinement. Initial molecular replacement solution was obtained by PHASER 38 in the CCP4 suite, using the 3.4 Å d-OR receptor structure (PDB 4EJ4) with deleted T4L, and BRIL from A 2A AR (PDB 4EIY) as independent search models. The resulting BRIL-dOR(DN/DC) model was refined by manually building in the excessive 2F o -F c density and by repetitive cycling between COOT 39 , REFMAC5 40 , and simulated annealing using PHENIX 41 until convergence. Ten translation, libration and screw-rotation atomic displacement (TLS) groups were used throughout refinement. The elongated electron density tubes near the protein hydrophobic surface were modelled as oleic acids, with the exception of the few that were better fit with monooleins, the major lipid component used for crystallization. The data collection and refinement statistics are shown in Extended Data Table 1 . d-OR b-arrestin-recruitment assay. Assays were performed using modifications of the original Tango assay 42 as described previously 43, 44 . In brief, d-OR constructs were codon optimized for mammalian expression and synthesized by Blue Heron Biotech, and inserted into the modular vector system (described in ref. 42 ) with all constructs confirmed by automated double-stranded DNA sequencing. HTLA cells (provided by R. Axel) were transfected by the calcium phosphate precipitation method. The next day, the cells were plated in DMEM supplemented with 1-2% dialysed FBS into Poly-L-Lys-coated 384-well white clear bottom cell culture plates at a density of 15,000 cells per well in a total volume of 50 ml. The following day, ligand solutions were prepared in filtered assay buffer (20 mM HEPES, 1 3 Hanks' balanced salt solution (HBSS), pH 7.40) at 3.53 and added to cells (20 ml per well) for overnight incubation (16-20 h ). The next day, media and drug solutions were removed and 20 ml per well of Bright-Glo reagent (Promega, 1:20 dilution in assay buffer) was added. Plates were incubated for 20 min at room temperature in the dark before being counting using a TriLux luminescence reader (1 s per well). To determine basal and constitutive activity of wild-type d-OR and N131A or N131V mutant d-ORs, HTLA cells were transfected as above at 0.5-5 mg DNA per 15-cm dish. An aliquot of the transfected cells was plated and incubated for overnight without agonist stimulation, and luminescence was determined as above. The remainders of the transfected cells were subjected to membrane preparation and binding assays to estimate receptor expression levels with 3 H-naltrindole (see below). Data were subjected to nonlinear least-squares regression analysis using the sigmoidal dose-response function provided in GraphPad Prism 5.0 or 6.0. Data of four independent experiments (n 5 4) performed in quadruplicate are presented as relative luminescence unit (Fig. 3) or as percentage of BW373U86 (Fig. 4) . cAMP assays. HEK293T (ATCC CRL-11268, Manassas) cells were co-transfected with human d-OR or various mutants along with a split-luciferase-based cAMP biosensor (GloSensor; Promega) and assays performed in a manner similar to previous studies with Ga i -coupled receptors 45 . Transfected cells were plated into Poly-L-Lys-coated 384-well white clear bottom cell culture plates with DMEM 1 1% dialysed FBS at a density of 15,000 cells per 40 ml per well overnight. On the day of the assay, cells were removed of culture medium and received 20 ml per well of assay buffer (20 mM HEPES, 1 3 HBSS, pH 7.40) followed by addition of 10 ml of 33 drug solutions for 15 min at room temperature. To measure agonist activity for Ga i -coupled receptors, 10 ml luciferin (4 mM final concentration) supplemented with isoproterenol (400 nM final concentration) were added to activate G s via endogenous b 2 -adrenergic receptors, and luminescence intensity was quantified 15 min later. Data were normalized compared to the agonist BW373U86 and regressed using the sigmoidal dose-response function. Data of four independent experiments (n 5 4) conducted in quadruplicate are presented as percentage of BW373U86 (Fig. 4) . Analyses were performed using the software GraphPad Prism. Radioligand binding assays. H-naltrindole binding assays were performed using Sf9 membrane fractions expressing the crystallization construct BRIL-dOR(DN/ DC) or HEK293 T membrane preparations transiently expressing wild-type or mutant d-OR receptors. HEK293 T cells were transfected to make membranes and binding assays were set up in 96-well plates as described previously 46 . To examine the effects of sodium on ligand binding at d-OR receptors, all binding assays were conducted in the d-OR binding buffer (50 mM Tris HCl, 2 mM EDTA, pH 7.40) in the absence or presence of NaCl at designed concentrations. Saturation binding assays with 0.2-30 nM for 2 h at room temperature in the dark, and terminated by rapid vacuum filtration onto chilled 0.3% PEI-soaked GF/A filters followed by three quick washes with cold washing buffer (50 mM Tris HCl, pH 7.40) and quantified as described previously 46 . Results (with or without normalization) were analysed using GraphPad Prism using one-site, two-site, or allosteric IC 50 shift models where indicated. Figure 3 ARTICLE RESEARCH
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